Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novo’s Cell Therapy Partner Heartseed Goes Public on TSE
July 31, 2024
- Foreign Pharma Sales in Japan Likely to Fall for 2nd Straight Year in 2024: Fuji Keizai
July 31, 2024
- JCR Ditches Temcell Program for nHIE Indication
July 31, 2024
- Chugai to Practically Scrap Mandatory Retirement Age in 2026
July 30, 2024
- Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
- Astellas Gets EMA Blessing for Gastric Cancer Drug Zolbetuximab
July 30, 2024
- Padcev-Keytruda Nears EU Nod for 1st Line Bladder Cancer
July 30, 2024
- Xocova Grabs Near-70% Share among Oral COVID Meds in Japan: Shionogi
July 30, 2024
- Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
- AZ, United Immunity to Tie Up on Drug Delivery Tech Research
July 29, 2024
- Otsuka Ups H1 Earnings Forecast on Brisk Business
July 29, 2024
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
- Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
July 26, 2024
- Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
- Merck, GTRI Tie Up in Development of Parkinson’s Gene Therapy
July 26, 2024
- Intage, Niigata University Tie Up on Megalin Antagonist Development
July 26, 2024
- Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
- Amazon Launches Online Pharmacy Service in Japan
July 25, 2024
- Novo, Mitsubishi Logistics to Launch Pilot Drug Transport Using Electric Truck
July 25, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…